Pharmaceuticals

Clever Leaves

Clever Leaves released FY2023 Q3 earnings on November 9, 2023 (EST): Actual Revenue $3.82M (Forecast $5.2M), Actual EPS -$3.2509 (Forecast -$2.1)

Clever Leaves released FY2021 Q4 earnings on March 24, 2022 (EST), with actual revenue of 4.194 M USD (forecast 4.056 M USD) and EPS of -27.3204 (forecast -18.6)

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

礼来

ROCHE HOLDINGS AG

罗氏(ADR)

阿斯利康

诺华制药

诺和诺德公司

中外制药(ADR)

UCB(ADR)

第一三共株式会社(ADR)

大冢制药(ADR)

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap